ARHGEF3 enhances ACLY protein stability by reducing acetylation at Lys17 and Lys86 of ACLY, leading to the dissociation of ACLY from its E3 ligase, NEDD4, making it a promising therapeutic target in non‐small cell lung cancer.278. Here, ACLY is linked to lung cancer.